FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy

81

KENILWORTH, N.J.–(BUSINESS WIRE)–<a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank">$MRK</a> <a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank">#MRK</a>–FDA Approves KEYTRUDA as Monotherapy for Metastatic SCLC with Disease Progression on or After Platinum-Based Chemotherapy and One Other Prior Therapy http://www.businesswire.com/news/home/20190618005294/en/FDA-Approves-Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Monotherapy-Patients/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==

- Advertisement -